UY35864A - Composiciones y métodos para reducir eventos adversos cardiovasculares graves - Google Patents
Composiciones y métodos para reducir eventos adversos cardiovasculares gravesInfo
- Publication number
- UY35864A UY35864A UY0001035864A UY35864A UY35864A UY 35864 A UY35864 A UY 35864A UY 0001035864 A UY0001035864 A UY 0001035864A UY 35864 A UY35864 A UY 35864A UY 35864 A UY35864 A UY 35864A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- methods
- adverse events
- serious cardiovascular
- cardiovascular adverse
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 230000007211 cardiovascular event Effects 0.000 abstract 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 2
- 229960001058 bupropion Drugs 0.000 abstract 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 2
- 229960003086 naltrexone Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 239000001115 mace Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a composiciones, kits, usos, sistemas y métodos para utilizar nalt rexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos car diovasculares graves (MACE, major adverse cardiovascular events) en los sujetos. La presente solici tud también se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y b upropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913216P | 2013-12-06 | 2013-12-06 | |
US201361914938P | 2013-12-11 | 2013-12-11 | |
US201461984580P | 2014-04-25 | 2014-04-25 | |
US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35864A true UY35864A (es) | 2015-07-31 |
Family
ID=52575014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035864A UY35864A (es) | 2013-12-06 | 2014-12-04 | Composiciones y métodos para reducir eventos adversos cardiovasculares graves |
Country Status (33)
Country | Link |
---|---|
US (8) | US8969371B1 (es) |
EP (2) | EP3076971B1 (es) |
JP (2) | JP6665094B2 (es) |
KR (3) | KR20230152800A (es) |
CN (3) | CN117159547A (es) |
AU (1) | AU2014360492A1 (es) |
BR (1) | BR112016012755A2 (es) |
CA (1) | CA2932127C (es) |
CL (1) | CL2016001362A1 (es) |
CR (1) | CR20160313A (es) |
CY (1) | CY1125114T1 (es) |
DK (1) | DK3076971T3 (es) |
EA (1) | EA201690964A1 (es) |
EC (1) | ECSP16057765A (es) |
ES (1) | ES2903391T3 (es) |
HR (1) | HRP20220058T1 (es) |
HU (1) | HUE057551T2 (es) |
IL (3) | IL300870A (es) |
JO (1) | JOP20140344B1 (es) |
LT (1) | LT3076971T (es) |
MX (2) | MX2016007231A (es) |
PE (1) | PE20161034A1 (es) |
PL (1) | PL3076971T3 (es) |
PT (1) | PT3076971T (es) |
RS (1) | RS62846B1 (es) |
RU (1) | RU2711638C2 (es) |
SG (1) | SG10201808055QA (es) |
SI (1) | SI3076971T1 (es) |
TN (1) | TN2016000231A1 (es) |
TW (1) | TWI661826B (es) |
UY (1) | UY35864A (es) |
WO (1) | WO2015085044A1 (es) |
ZA (1) | ZA201603831B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2316456T3 (en) | 2003-04-29 | 2017-09-11 | Orexigen Therapeutics Inc | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
ES2402522T3 (es) | 2005-11-22 | 2013-05-06 | Orexigen Therapeutics, Inc. | Composiciones y procedimientos para aumentar la sensibilidad a la insulina |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
LT3730132T (lt) * | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
JP6731540B2 (ja) * | 2016-08-11 | 2020-07-29 | 華為技術有限公司Huawei Technologies Co.,Ltd. | 免許不要帯域に基づく無線通信方法、基地局、及び端末デバイス |
WO2023107640A1 (en) * | 2021-12-09 | 2023-06-15 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
EP0103636B1 (en) | 1982-03-16 | 1990-09-12 | Rockefeller University | Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
DE3883606T2 (de) | 1987-05-04 | 1994-01-20 | Lilly Co Eli | Verwendung von Fluoxetin zur Behandlung des Diabetes. |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
ATE214276T1 (de) | 1994-09-19 | 2002-03-15 | Du Pont Pharm Co | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
AU724993B2 (en) | 1996-03-13 | 2000-10-05 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
ES2277357T3 (es) | 1996-05-07 | 2007-07-01 | Veroscience Llc | Metodo y compuesto para el tratamiento de desordenes de metabolismo de lipidos y glucosa. |
ES2184127T3 (es) | 1996-06-28 | 2003-04-01 | Ortho Mcneil Pharm Inc | Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad. |
US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
CN1155410C (zh) | 1997-10-03 | 2004-06-30 | 卡里药品公司 | 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物 |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
EP1215963A4 (en) | 1999-09-15 | 2005-07-27 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
JP2003520234A (ja) | 2000-01-22 | 2003-07-02 | アルバート シャルマン | 薬物中毒の治療方法 |
PT1255547E (pt) | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Composições de libertação controlada contendo agonistas e antagonistas opióides |
US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
WO2002100382A2 (en) | 2001-06-08 | 2002-12-19 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
AU2002319774B2 (en) | 2001-08-06 | 2005-04-21 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
NZ530971A (en) | 2001-08-06 | 2004-08-27 | Euro Celtique S | Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
MXPA04011203A (es) | 2002-05-17 | 2005-07-14 | Univ Duke | Metodo para tratar la obesidad. |
PL371596A1 (en) | 2002-05-17 | 2005-06-27 | Merck Patent Gmbh | Use of compounds that are effective as selective opiate receptor modulators |
US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
JP2006507251A (ja) | 2002-09-13 | 2006-03-02 | エーザイ株式会社 | 振せんの治療方法 |
US20040192715A1 (en) | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US20050038062A1 (en) | 2003-04-14 | 2005-02-17 | Burns Lindsay H. | Methods and materials for the treatment of pain comprising opioid antagonists |
DK2316456T3 (en) | 2003-04-29 | 2017-09-11 | Orexigen Therapeutics Inc | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
CA2525366A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
CA2539027C (en) | 2003-09-25 | 2010-02-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
EP1734955A2 (en) | 2004-01-13 | 2006-12-27 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss |
US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
CA2565154A1 (en) | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
AU2005271574A1 (en) | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
ES2402522T3 (es) | 2005-11-22 | 2013-05-06 | Orexigen Therapeutics, Inc. | Composiciones y procedimientos para aumentar la sensibilidad a la insulina |
WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
TW200803901A (en) | 2005-11-28 | 2008-01-16 | Orexigen Therapeutics Inc | Methods of treating anxiety disorders |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
JP5478245B2 (ja) | 2006-06-05 | 2014-04-23 | オレキシジェン・セラピューティクス・インコーポレーテッド | ナルトレキソンの徐放型配合物 |
PT2719378T (pt) | 2006-06-19 | 2016-11-02 | Alpharma Pharmaceuticals Llc | Composições farmacêuticas |
CA2693992C (en) | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
KR101735466B1 (ko) | 2006-11-09 | 2017-05-15 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
NO2646011T3 (es) | 2010-12-03 | 2018-01-13 | ||
LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en active Application Filing
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko not_active Application Discontinuation
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 MX MX2016007231A patent/MX2016007231A/es unknown
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Application Discontinuation
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active IP Right Grant
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35864A (es) | Composiciones y métodos para reducir eventos adversos cardiovasculares graves | |
CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
CL2017003356A1 (es) | Moduladores cot y métodos de uso de los mismos | |
CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
CR20150316A (es) | Compuestos y sus métodos de empleo | |
CR20160069A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
GT201400278A (es) | Métodos para el tratamiento del sobrepeso y de la obesidad | |
BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
GT201700194A (es) | Formulación de combinación de tesofensina y betabloqueante | |
SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
CL2018003188A1 (es) | Procedimiento para la preparación de cuerpos moldeados para la administración a animales. | |
AR114030A1 (es) | Triterpenos pentacíclicos en el tratamiento de una patología oral-dental | |
BR112018014171A2 (pt) | composições biofotônicas para o tratamento de otite externa | |
ES2478793B2 (es) | Composición de nanofilamentos para el tratamiento de tumores | |
BR112018072255A2 (pt) | azasteroides para tratamento de tuberculose | |
AR120476A2 (es) | Método para tratar un sujeto que tiene un riesgo de sufrir un evento cardiovascular grave; método para prevenir o retrasar el inicio de dicho evento, método para tratar un sujeto por sobrepeso u obesidad y uso de naltrexona y bupropión para la preparación de un medicamento | |
AR118751A2 (es) | Tratamiento de cáncer utilizando receptor de antígeno quimérico anti-cd19 | |
CR20140489A (es) | Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20221213 |